Authors
Katarina Tomović Pavlović, Andrija Šmelcerović, Marko Anderluh
Published in
European journal of medicinal chemistry. Volume 321. Issue Pt 3. Pages 119482. Oct 31, 2026. Epub Oct 31, 2026.
Abstract
In multifactorial disorders, such as type 2 diabetes (T2D), a single-target approach rarely leads to satisfactory therapeutic outcome. The multi-target approach offers benefits, but its drug development faces a range of challenges. Several druggable enzyme targets involved in T2D and its complications have been identified, including clinically validated (dipeptidyl peptidase-4 (DPP-4), α-glucosidase, α-amylase, angiotensin converting enzyme (ACE), neprilysin (NEP)), clinically investigated (11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), protein tyrosine phosphatase 1B (PTP1B), methionine aminopeptidase 2 (MetAP2)), the widely investigated target aldose reductase (AR) which has been studied in clinical and preclinical research, and scientifically validated, preclinical/early-clinical target fructose-1,6-bisphosphatase (FBPase). There are data in the literature on dual/triple inhibitors of DPP-4, α-glucosidase, α-amylase, AR, NEP, PTP1B, and ACE, combined with each other. Within the polypharmacological paradigm, retrospective analyses of some successful drugs revealed them to be multi-targeting. Some approved inhibitors showed inhibitory potential on other enzymes evaluated here. Given the structural diversity and vast number of potential targets, the proposal is to evaluate approved agents (starting with DPP-4 inhibitors) against other listed enzymes, thereby shortening the development time frame of novel candidates. Furthermore, the suggested guideline is: once a compound demonstrates inhibitory activity against one of the target enzymes, its activity should be evaluated against other enzymes involved in T2D pathophysiology to facilitate discovery of multi-targeting drug candidates. This can be done by merging pharmacophore design, which is frequently used to combine the essential binding features into a single hybrid chemical entity. Efforts made employing this strategy are also reviewed here.
PMID:
42998519
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0